Alkermes plc (ALKS), which delivered a strong quarter marked by solid financial and commercial execution early this month, touched a new high of $38.46 yesterday. With the successful completion of the Avadel acquisition, a strengthened financial profile, and an accelerated entry into the commercial sleep medicine market at scale, the company sees a transformative growth opportunity ahead.
This commercial stage company is focused on developing medicines designed to help people living with complex and difficult-to-treat psychiatric and neurological disorders, including addiction, serious mental illness and sleep disorders. Its portfolio of commercial products includes approved medicines like:
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com